Man­u­fac­tur­ing roundup: WuXi con­tin­ues its ex­pan­sion dri­ve with an­oth­er plant open­ing in Changzhou; Swiss biotech nets an­oth­er ac­qui­si­tion

The CD­MO WuXi STA has been rapid­ly ex­pand­ing over the past year, and its next open­ing will ex­pand its of­fer­ing in the pep­tide sec­tor.

WuXi has opened two new large-scale oligonu­cleotide and pep­tide man­u­fac­tur­ing fa­cil­i­ties at its cam­pus in Changzhou, Chi­na, ac­cord­ing to the com­pa­ny. How­ev­er, the fi­nan­cial and em­ploy­ment de­tails have not been dis­closed to End­points News.

The new 30,000 square-foot fa­cil­i­ty for oligonu­cleotide de­vel­op­ment and man­u­fac­tur­ing con­tains four oligonu­cleotide pro­duc­tion lines and more than 20 small- to mid-scale pro­duc­tion lines that should in­crease the over­all man­u­fac­tur­ing ca­pac­i­ty of a sin­gle syn­the­sis run from 1.9 mol to 6.0 mol.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER